Company: ATRA
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001193125-25-276219
Chunk: 7

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 2
Chunk 7
---
 limited partnership. Pursuant to the terms of the HCRx Agreement, we received a total investment amount of $31.0 million in exchange for HCRx being entitled to receive a portion of the tiered, sales-based royalties for Ebvallo, in amounts ranging from the mid-single digits to significant double digits, as well as certain milestone payments, both related to the Initial Territory and otherwise payable to us by Pierre Fabre. The total royalties and milestones payable to HCRx related to the Initial Territory under the HCRx Agreement are capped between 185% and 250% of the total investment amount by HCRx, dependent upon the timing of such royalty and milestone payments to HCRx.